Proqr Therapeutics (PRQR)

Trade PRQR now with
10/5/2020 7:12:48 AM ProQR Appoints Naveed Shams As Chief Scientific Officer
3/31/2020 6:10:39 AM ProQR Announces Positive Findings From Interim Analysis In Phase 1/2 Trial Of QR-421a For Usher Syndrome
10/18/2019 8:29:21 AM ProQR Reports Closing Of Public Offering Of Ordinary Shares
10/16/2019 12:13:49 AM ProQR Prices Public Offering Of 9.09 Mln Ordinary Shares At $5.50/Shr
10/10/2019 6:05:16 AM ProQR Announces Positive Top-Line Results From Phase 1/2 Study Of Sepofarsen In LCA10 Patients
10/7/2019 7:19:45 AM ProQR To Present Top-Line Results From The Phase 1/2 Study Of Sepofarsen In LCA10 Patients Ahead Of AAO
9/9/2019 7:06:23 AM ProQR Gets Fast Track Designation From FDA For QR-1123
8/12/2019 7:08:48 AM ProQR Says FDA Cleared IND Application For QR-1123
2/27/2019 7:11:51 AM ProQR Therapeutics Q4 Net Loss EUR 13.0 Mln Or EUR 0.33/shr Vs Loss EUR 11.3 Mln Or EUR 0.39/Shr Last Year
1/7/2019 7:19:10 AM ProQR Therapeutics Reaches Agreement With FDA On Design Of Phase 2/3 Pivotal Trial For QR-110
1/2/2019 7:04:15 AM ProQR Therapeutics Receives Fast Track Designation From FDA For QR-421a
12/10/2018 7:04:10 AM ProQR Receives EUR 4.7 Mln In Innovation Credit From Dutch Government For QR-110 For LCA10
12/4/2018 7:03:47 AM ProQR Announces Clearance Of IND To Start Clinical Trial Of QR-421a In Usher Syndrome Type 2 Patients
11/7/2018 7:14:41 AM ProQR Therapeutics N.V. Q3 Net Loss €6.0 Mln Or €0.18/shr Vs. Loss €10.5 Mln Or €0.42/shr Last Year